北京时间2024年11月5日,生物制药公司 Apellis Pharmaceuticals Inc. (APLS)股价当日大幅下跌14.53%,跌至26美元左右,引发了市场的广泛关注。
APLS股价暴跌的主要原因是该公司近期公布的2024年第三季度业绩不佳。具体来看,APLS第三季度亏损46美分/每股,远高于市场预期的30美分/每股亏损。公司营业收入为1.968亿美元,也低于预期的2.0035亿美元。业绩低于预期,加上公司主打产品SYFOVRE注射液遭到欧盟否定,给未来业务带来不确定性,导致投资者对该公司前景失去信心,纷纷抛售股票。
SYFOVRE是APLS一款治疗地理性黄斑变性疾病的创新产品,本应成为未来营收增长的主要动力。但由于遭欧盟人用药委员会否定,该产品的上市前景存在不确定性,加剧了投资者对APLS的担忧情绪。公司还预计SYFOVRE于2025年初获得其他国家和地区的监管决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.